STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

Dexcom Inc (DXCM) chair Kevin Sayer sells 26,756 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Dexcom Inc Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026 at a weighted average price of $76.3193 per share, in multiple trades between $75.80 and $76.62. The sale was made under a Rule 10b5-1 trading plan adopted on February 18, 2026 for orderly dispositions of his holdings. Following this sale, he directly holds 328,970 shares, including 106,972 unvested restricted stock units that were granted in 2024–2026 and will vest through 2028.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider SAYER KEVIN R
Role Executive Chair
Sold 26,756 shs ($2.04M)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 26,756 $76.3193 $2.04M
Holdings After Transaction: Common Stock — 328,970 shares (Direct)
Footnotes (3)
  1. F1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
  2. F2. This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. F3. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Shares sold 26,756 shares Common stock sold by Kevin R. Sayer on July 20, 2026
Weighted average sale price $76.3193 per share Common stock sale on July 20, 2026
Post-transaction holdings 328,970 shares Direct holdings after July 20, 2026 sale
Unvested RSUs 106,972 units Included within total post-transaction holdings
RSUs grant 2026 32,749 units Granted March 8, 2026; vest through March 8, 2027
RSUs grant 2025 56,993 units Granted March 8, 2025; vest through March 8, 2028
RSUs grant 2024 17,230 units Granted March 8, 2024; vest through March 8, 2027
10b5-1 plan adoption date February 18, 2026 Date Kevin R. Sayer adopted trading plan
10b5-1 Plan regulatory
"Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
restricted stock units financial
"Included in this number are 106,972 unvested restricted stock units, 32,749"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price above reflects the weighted average sale price. The Reporting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Dexcom (DXCM) report for Kevin R. Sayer?
Dexcom reported that Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026. The weighted average sale price was $76.3193 per share, executed in multiple trades between $75.80 and $76.62.

Was the recent Dexcom (DXCM) insider sale under a Rule 10b5-1 plan?
Yes. The sale was made under a Rule 10b5-1 Plan adopted by Kevin R. Sayer on February 18, 2026. The plan is described as allowing the orderly disposition of shares owned by him, and this transaction was executed pursuant to that plan.

How many Dexcom (DXCM) shares does Kevin R. Sayer hold after the sale?
After the July 20, 2026 transaction, Kevin R. Sayer directly holds 328,970 Dexcom shares. This total includes 106,972 unvested restricted stock units that are scheduled to vest over future periods through March 8, 2028.

What unvested RSUs does Kevin R. Sayer have at Dexcom (DXCM)?
Kevin R. Sayer holds 106,972 unvested restricted stock units. These include 32,749 RSUs granted March 8, 2026; 56,993 RSUs granted March 8, 2025; and 17,230 RSUs granted March 8, 2024, vesting through 2027–2028.

What price range applied to Kevin R. Sayer’s Dexcom (DXCM) share sale?
The July 20, 2026 sale was executed in multiple trades at prices from $75.80 to $76.62 per share. The reported transaction price of $76.3193 represents the weighted average sale price across those trades, according to the filing footnote.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SAYER KEVIN R
(Last)(First)(Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Executive Chair
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/20/2026S26,756(1)D$76.3193(2)328,970(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
2. This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Remarks:
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR